<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/814" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/814/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/814/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_814"><akn:num>814</akn:num><akn:heading>Removal of exemption of certain drugs</akn:heading><akn:content><akn:p>§ 814. Removal of exemption of certain drugs(a) Removal of exemptionThe Attorney General shall by regulation remove from exemption under section 802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.


(b) Factors to be consideredIn removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—(1) the scope, duration, and significance of the diversion;

(2) whether the drug or group of drugs is formulated in such a way that it cannot be easily used in the illicit production of a controlled substance; and

(3) whether the listed chemical can be readily recovered from the drug or group of drugs.


(c) Specificity of designationThe Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection (a) to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of diversion and other relevant factors, that the diversion will not be limited to that particular drug or group of drugs.


(d) Reinstatement of exemption with respect to particular drug products(1) ReinstatementOn application by a manufacturer of a particular drug product that has been removed from exemption under subsection (a), the Attorney General shall by regulation reinstate the exemption with respect to that particular drug product if the Attorney General determines that the particular drug product is manufactured and distributed in a manner that prevents diversion.


(2) Factors to be consideredIn deciding whether to reinstate the exemption with respect to a particular drug product under paragraph (1), the Attorney General shall consider—(A) the package sizes and manner of packaging of the drug pro</akn:p></akn:content><akn:subsection eId="subsec_814_a"><akn:num>(a)</akn:num><akn:heading>Removal of exemption</akn:heading><akn:content><akn:p>(a) Removal of exemption The Attorney General shall by regulation remove from exemption under section 802(39)(A)(iv) of this title a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_814_b"><akn:num>(b)</akn:num><akn:heading>Factors to be considered</akn:heading><akn:content><akn:p>(b) Factors to be considered In removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_814_c"><akn:num>(c)</akn:num><akn:heading>Specificity of designation</akn:heading><akn:content><akn:p>(c) Specificity of designation The Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection (a) to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of diversion and other relevant factors, that the diversion will not be limited to that particular drug or group of drugs.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_814_d"><akn:num>(d)</akn:num><akn:heading>Reinstatement of exemption with respect to particular drug products</akn:heading><akn:content><akn:p>(d) Reinstatement of exemption with respect to particular drug products</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>